MiMedx Group (NASDAQ:MDXG) Trading 0.7% Higher – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG) traded up 0.7% during mid-day trading on Monday . The stock traded as high as $4.35 and last traded at $4.33. 737,038 shares changed hands during mid-day trading, a decline of 40% from the average session volume of 1,228,400 shares. The stock had previously closed at $4.30.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings downgraded MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Craig Hallum dropped their price objective on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Wall Street Zen lowered MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Citizens Jmp reduced their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MiMedx Group presently has an average rating of “Moderate Buy” and an average price target of $8.50.

MiMedx Group Stock Performance

The company’s 50-day moving average price is $3.81 and its 200 day moving average price is $4.36. The stock has a market capitalization of $644.95 million, a PE ratio of 21.65 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The company had revenue of $58.99 million for the quarter, compared to analysts’ expectations of $65.80 million. On average, equities research analysts expect that MiMedx Group, Inc will post -0.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kemnay Advisory Services Inc. bought a new position in shares of MiMedx Group in the 4th quarter worth approximately $48,000. Sunbelt Securities Inc. purchased a new position in shares of MiMedx Group in the 1st quarter valued at approximately $42,000. Jain Global LLC bought a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $73,000. Virtu Financial LLC bought a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $78,000. Finally, Headlands Technologies LLC purchased a new stake in MiMedx Group in the second quarter worth $72,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.